U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07897968) titled 'GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors' on Oct. 20.
Brief Summary: This study will test a CAR T-cell treatment combined with bevacizumab in children and young adults with relapsed or refractory neuroblastoma, Ewing sarcoma, or osteosarcoma.
The CAR T-cell treatment, called GD2IL18CART, is made from a patient's own T cells. The T cells are genetically modified to recognize GD2, a molecule found on the surface of these cancers, and to release the immune-stimulating protein interleukin-18 (IL-18) when they encounter tumor cells. Bevacizumab is an antibody that blocks vascular endoth...